ASX Announcements
Filter By Year:
| 8 Oct 2023 | 11:31pm | BIOXYNE LIMITED | no | Change of Director’s Interest Notice opens new window | 170KB |
|
|
| 4 Oct 2023 | 10:40pm | BIOXYNE LIMITED | no | AGM Date 2023 and Closing Date for Director Nominations opens new window | 537KB |
|
|
| 29 Sep 2023 | 8:31am | BIOXYNE LIMITED | no | Annual Report to shareholders opens new window | 1780KB |
|
|
| 29 Sep 2023 | 8:26am | BIOXYNE LIMITED | no | Appendix 4G and Corporate Governance Statement opens new window | 669KB |
|
|
| 31 Aug 2023 | 9:57am | BIOXYNE LIMITED | yes | Preliminary Final Report opens new window | 603KB |
|
|
| 14 Aug 2023 | 11:34pm | BIOXYNE LIMITED | no | Bioxyne Signs Joint Venture with CanXChange opens new window | 586KB |
|
|
| 31 Jul 2023 | 2:53am | BIOXYNE LIMITED | yes | Quarterly Activities/Appendix 4C Cash Flow Report opens new window | 989KB |
|
|
| 17 Jul 2023 | 4:14am | BIOXYNE LIMITED | yes | BLS Extends Amazon Footprint into US and Japan opens new window | 632KB |
|
|
| 13 Jun 2023 | 12:05am | BIOXYNE LIMITED | no | Bioxyne Launches BLS Clinics – Online Healthcare opens new window | 628KB |
|
|
| 8 Jun 2023 | 7:36am | BIOXYNE LIMITED | no | Becoming a substantial holder opens new window | 214KB |
|
|
| 31 May 2023 | 8:30am | BIOXYNE LIMITED | no | Becoming a substantial holder opens new window | 1245KB |
|
|
| 31 May 2023 | 8:29am | BIOXYNE LIMITED | no | Change in substantial holding opens new window | 508KB |
|
|
| 25 May 2023 | 12:24am | BIOXYNE LIMITED | no | Notification regarding unquoted securities – BXN opens new window | 27KB |
|
|
| 23 May 2023 | 7:44am | BIOXYNE LIMITED | no | Ceasing to be a substantial holder X 2 opens new window | 4164KB |
|
|
| 23 May 2023 | 7:42am | BIOXYNE LIMITED | no | Becoming a substantial holder opens new window | 261KB |
|
|
| 23 May 2023 | 7:41am | BIOXYNE LIMITED | no | Becoming a substantial holder opens new window | 18169KB |
|
|
| 23 May 2023 | 3:42am | BIOXYNE LIMITED | no | Final Directors Interest Notice X 2 opens new window | 295KB |
|
|
| 23 May 2023 | 3:41am | BIOXYNE LIMITED | no | Initial Directors Interest Notice X 2 opens new window | 258KB |
|
|
| 22 May 2023 | 9:26am | BIOXYNE LIMITED | no | Cleansing Notice opens new window | 530KB |
|
|
| 22 May 2023 | 9:05am | BIOXYNE LIMITED | no | Application for quotation of securities – BXN opens new window | 27KB |
|
|
| 22 May 2023 | 8:59am | BIOXYNE LIMITED | no | Application for quotation of securities – BXN opens new window | 27KB |
|
|
| 22 May 2023 | 2:26am | BIOXYNE LIMITED | no | Bioxyne Completes Acquisition of Breathe Life Sciences opens new window | 728KB |
|
5-May-2023 Results of Meeting
24-Apr-2023 Quarterly Activities/Appendix 4C Cash Flow Report
20-Mar-2023 Bioxyne Executes SPA to Acquire Breathe Life Sciences
27-Feb-2023 Becoming a substantial holder
23-Feb-2023 Half Yearly Report and Accounts
27-Jan-2023 Quarterly Activities/Appendix 4C Cash Flow Report
19-Dec-2022 BXN to Acquire Health & Wellness Co Breathe Life Sciences
30-Nov-2022 New Constitution
28-Nov-2022 Results of Meeting
16-Nov-2022 Cleansing Notice
16-Nov-2022 Application for quotation of securities – BXN
15-Nov-2022 Proposed issue of securities – BXN
3-Nov-2022 Notification of cessation of securities – BXN
31-Oct-2022 Quarterly Activities/Appendix 4C Cash Flow Report
28-Oct-2022 Letter to Shareholders on Annual General Meeting Notice
28-Oct-2022 Notice of Annual General Meeting/Proxy Form
26-Oct-2022 Cleansing Notice
24-Oct-2022 Joins Asian Partner & Sells 49% of Direct Selling Business
30-Sep-2022 Appendix 4G and Corporate Governance Statement
30-Sep-2022 Annual Report to shareholders
30-Aug-2022 Preliminary Final Report
28-Jul-2022 Quarterly Activities/Appendix 4C Cash Flow Report
30-Jun-2022 Initial Director’s Interest Notice
30-Jun-2022 Final Director’s Interest Notice
8-Jun-2022 Board and Management Changes
28-Apr-2022 Quarterly Activities/Appendix 4C Cash Flow Report
22-Feb-2022 Appendix 4D and Interim Report
31-Jan-2022 Quarterly Activities/Appendix 4C Cash Flow Report
30-Nov-2021 Results of Meeting
4-Nov-2021 Reinstatement to Official Quotation
4-Nov-2021 Bioxyne Not to Proceed with Proposed Acquisition
29-Oct-2021 Letter to Shareholders on Annual General Meeting
29-Oct-2021 Notice of Annual General Meeting/Proxy Form
29-Oct-2021 Suspension from Quotation
28-Oct-2021 Quarterly Activities/Appendix 4C Cash Flow Report
27-Oct-2021 Trading Halt
27-Oct-2021 Pause in Trading
30-Sep-2021 Appendix 4G and Corporate Governance Statement
30-Sep-2021 Annual Report to shareholders
30-Sep-2021 Explanatory Note to the 2021 Annual Report
31-Aug-2021 Preliminary Final Report
22-Jul-2021 Quarterly Activities/Appendix 4C Cash Flow Report
30-Apr-2021 Appendix 4C – quarterly
21-Apr-2021 Response to ASX Price Query
25-Feb-2021 Appendix 4D and Half Year Accounts
29-Jan-2021 Appendix 4C – Quarterly December 2020
26-Nov-2020 Results of Meeting
29-Oct-2020 Appendix 4C – quarterly
27-Oct-2020 Notice of Annual General
30-Sep-2020 Appendix 4G and Corporate Governance
30-Sep-2020 Annual Report to shareholders
31-Aug-2020 Preliminary Final Report
21-Aug-2020 Response to ASX Price Query
31-Jul-2020 Appendix 4C – quarterly
1-May-2020 Appendix 4C Revised
30-Apr-2020 Appendix 4C – quarterly
14-Apr-2020 Market Update
28-Feb-2020 Appendix 4D and Half Year Accounts
31-Jan-2020 Appendix 4C – quarterly
20-Jan-2020 Change of Share Registry
27-Nov-2019 Change of Directors Interest Notice X 4
27-Nov-2019 Appendix 3B
25-Nov-2019 Results of Meeting
31-Oct-2019 Appendix 4C – quarterly
25-Oct-2019 Notice of Annual General Meeting/Proxy Form
9-Oct-2019 Change of Director’s Interest Notice
30-Sep-2019 Annual Report to shareholders
30-Sep-2019 Explanatory Note to the 2019 Annual Report
30-Sep-2019 Appendix 4G and Corporate Governance Statement
28-Aug-2019 Preliminary Final Report
31-Jul-2019 Appendix 4C – quarterly
4-Jun-2019 Change of Director’s Interest Notice
29-Apr-2019 Appendix 4C – quarterly
1-Apr-2019 Market Update
20-Feb-2019 Appendix 4D and Half Year Accounts
30-Jan-2019 Appendix 4C – quarterly
21-Jan-2019 Final Director’s Interest Notice
17-Jan-2019 Director Resignation
21-Dec-2018 Change of Directors Interest Notice X 5
21-Dec-2018 Appendix 3B
29-Nov-2018 Results of Meeting
21-Dec-2018 Appendix 3B
29-Nov-2018 Results of Meeting
29-Oct-2018 Quarterly Activities Report
29-Oct-2018 Appendix 4C – quarterly
25-Oct-2018 Notice of Annual General Meeting/Proxy Form
16-Oct-2018 Change of Director’s Interest Notice
28-Sep-2018 Annual Report to shareholders
28-Sep-2018 Appendix 4G and Corporate Governance Statement
25-Sep-2018 Bioxyne Expands to Indonesia with Acquisition
31-Aug-2018 Preliminary Final Report
6-Aug-2018 Change of Director’s Interest Notice
27-Jul-2018 Quarterly Activities and Quarterly Cash Flow Report
16-Jul-2018 Change of Director’s Interest Notice
10-Jul-2018 Change of Director’s Interest Notice
22-Jun-2018 Change of Director’s Interest Notice
20-Jun-2018 Change of Director’s Interest Notice
12-Jun-2018 Bioxyne to Distribute GRAYNS Starch Reducing Rice Cooker
21-May-2018 Clarification to Announcement
21-May-2018 Expands to Thailand, Philippines, Myanmar, Cambodia,
4-May-2018Initial Director’s Interest Notice
1-May-2018 Appointment of Non-Executive Director
30-Apr-2018 Securities Trading Policy – Updated
27-Apr-2018 Quarterly Activities and Quarterly Cash Flow Reports
19-Mar-2018 Investor Update
1-Mar-2018 Response to ASX Query Letter
28-Feb-2018 Appendix 4D and Interim Financial Report
26-Feb-2018 Unique NZ Colostrum Honey Dairy Product for China and S.E.A
16-Feb-2018 Final Director’s Interest Notice
15-Feb-2018 Director Resignation
15-Feb-2018 Appendix 3B Corrected
30-Jan-2018 Quarterly Activities and Quarterly Cash Flow Report Dec 17
17-Jan-2018 Change of Director’s Interest Notice
16-Jan-2018 Additional New Products Launched for Direct Sales
19-Dec-2017 Appendix 3B
14-Dec-2017 Third Party Claim
11-Dec-2017 Appendix 3B
11-Dec-2017 Change of Directors Interest X 3
11-Dec-2017 Positive Bioxyne Gut Health Clinical Trial Results
7-Dec-2017 Change of Directors Interest Notice X 2
7-Dec-2017 Bioxyne Launches NZ Dairy Formula Product in South East Asia
7-Dec-2017 Appendix 3B Amended
5-Dec-2017 Appendix 3B
1-Dec-2017 Change of Share Registry
28-Nov-2017 Results of Meeting
15-Nov-2017 Letter to Optionholders
1-Nov-2017 Change of Director’s Interest Notice
27-Oct-2017 Appendix 3B
26-Oct-2017 Notice of Annual General Meeting/Proxy Form
25-Oct-2017 Quarterly Activities Report and Appendix 4C
25-Oct-2017 Malaysian Direct Selling Licence to Propel Bioxyne into MLM
17-Oct-2017 Appendix 3B
16-Oct-2017 Response to ASX Price Query Letter
12-Oct-2017 Appendix 3B
29-Dec-2016 Details of Company Address
24-Nov-2016 Results of Meeting
23-Nov-2016 AGM Notice – Amendment to Resolutions
21-Nov-2016 AGM – Amendment to Resolutions
18-Nov-2016 Final Director’s Interest Notice
18-Nov-2016 Director Resignation
2-Nov-2016 Launch of Two Products Containing PCC Onto Australian Market
26-Oct-2016 Quarterly Activities Report and Appendix 4C
24-Oct-2016 Notice of Annual General Meeting/Proxy Form
17-Oct-2016 Recruitment for Clinical Trial of Proprietary Probiotic PCC
29-Sep-2016 Annual Report to shareholders
29-Sep-2016 Appendix 4G and Corporate Governance Statement
12-Sep-2016 Becoming a substantial holder
9-Sep-2016 Ceasing to be a substantial holder
1-Sep-2016 Management Restructure
1-Sep-2016 Company Secretary Appointment/Details of Company Address
30-Aug-2016 Appendix 4E – Preliminary Final Report
28-Jul-2016 Appendix 4C – June Quarterly
23-Jun-2016 Bioxyne Commences New Clinical Trial
15-Jun-2016 Directors Equity Based Incentives